PDCD1 and lung cancer: A combination of erdafitinib and anti-PD1 (programmed cell death protein 1) therapy in an indigenous FGFR2K660N/p53mutant lung cancer mouse model demonstrated that combination treatment led to significant tumor regression and improved survival when compared to either treatment alone [151].